On October 11, 2024, Jon Congleton, the CEO of Mineralys Therapeutics Inc (MLYS, Financial), executed a sale of 15,271 shares of the company. According to the SEC Filing, the transaction occurred at an average price of $13.52 per share, totaling approximately $206,463.92. Following this transaction, the insider now owns 895,941 shares of the company.
Mineralys Therapeutics Inc (MLYS, Financial) is focused on developing targeted therapies for cardiovascular and kidney diseases. The company aims to address the unmet medical needs in these areas with innovative treatment options.
Over the past year, Jon Congleton has been active in the market with his shares of the company. The insider has sold a total of 153,127 shares and purchased 4,250 shares during this period. The recent transaction forms part of a broader trend observed within the company, where there have been 10 insider sells and 2 insider buys over the last year.
The shares of Mineralys Therapeutics Inc (MLYS, Financial) were trading at $13.52 on the day of the transaction. This pricing gives the company a market cap of approximately $681.255 million.
For further insights into the company's valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider sell event is part of a broader pattern of insider transactions at Mineralys Therapeutics Inc, which could be of interest to current and potential investors for monitoring the insider sentiment towards the stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
